10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-LILRB1 Reference Antibody (D2M Biotherapeutics patent anti-LILRB1)

Catalog # APR11370

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q8NHL6
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	70819


Additional Information

Target/Specificity	LILRB1 / ILT2 / CD85j
Expression system	CHO


Protein Information

Name	LILRB1 {ECO:0000303|PubMed:20600445, ECO:0000312|HGNC:HGNC:6605}
Function	Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:19304799, PubMed:29262349). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Expressed in B cells, monocytes and various dendritic cell (DC) subsets including myeloid, plasmacytoid and tolerogenic DCs (at protein level) (PubMed:20448110, PubMed:24453251, PubMed:9285411, PubMed:9842885). Expressed in decidual macrophages (at protein level) (PubMed:19304799). Expressed in decidual NK cells (at protein level) (PubMed:29262349).


Images



Anti-LILRB1 Reference Antibody (D2M Biotherapeutics patent anti-LILRB1) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-LILRB1 Reference Antibody (D2M Biotherapeutics patent anti-LILRB1) is 100%, determined by SEC-HPLC.



Immobilized Human LILRB1-ECD-His at 2 μg/mL can bind D2M Biotherapeutics patent anti-LILRB1, EC50= 0.06541 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.